COVID-19

The country's COVID-19 death toll is nearing 1 million.

Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children.

Respondents to a recent poll were still hesitant to get the Pfizer-BioNTech shot.

Data from COVID-19 vaccine distribution could spark improvements for future vaccination efforts.

A recent study evaluated 4 million Tweets published in 2021.

There are no easy solutions for people who gained insurance coverage through Medicaid.

The amended authorizations apply to the Pfizer-BioNTech and Moderna COVID-19 vaccines.

Attitudes change over time but people need convincing.

Moderna has released preliminary data from the company's phase 2/3 trial of the vaccine in children aged younger than 6 years.

The AMA objects to pharmacy-based clinics as an access point for COVID-19 treatments.

The facilities will be inspected between March 9 and June 9, 2022.

NACDS CEO responds to comments by AMA president.

President Biden’s recent State of the Union address included a pharmacy Test to Treat iniativie for COVID-19.

Rural areas lag well behind their urban counterparts when it comes to COVID-19 vaccinations

Molnupiravir is an oral antiviral for the treatment of mild to moderate COVID-19 in adults at high risk of severe disease.

COVID-19 updates and news to know as of February 28, 2022.

A large cohort study offers important data on what factors are frequently tied to severe cases of COVID-19 in the pediatric population.

The days of blanket mitigation strategies to protect children from COVID-19 are becoming a thing of the past. One model sheds light onto determining when strategies can be relaxed.

Recent treatment may affect the antibody response, particularly among those with hematologic cancers.

COVID-19 updates and news to know as of February 21, 2022.

Does anxiety justify an exemption from vaccine mandates among health care workers?

Patients with chronic lymphocytic leukemia experienced functional T cell and antibody responses after receiving a vaccine for COVID-19.

NVX-CoV2373 was evaluated in adolescents aged 12 to 17 years.

The FDA meeting to discuss extending the Pfizer/BioNTech EUA to children aged 6 months to 4 years has been postponed until data on a third dose has been studied.

The safety of the Pfizer/BioNTech COVID-19 vaccine in pregnant women, for both mother and baby, has been dependent on observation during the rollout. A large population trial provides further support for the vaccine’s safety.